Figure 2. Effect of bevacizumab, anti-CTGF antibody and combined bevacizumab/anti-CTGF on the proliferation rate of human RPE cells. Cell proliferation ELISA assay was carried out as described in the methods. Briefly RPE cells treated by 0.25, 0.5 and 0.8 mg/ml of bevacizumab or 10 µg/ml of anti-CTGF or both of bevacizumab (0.8 mg/ml)/anti-CTGF (10 µg/ml). After 48 h cultures were harvested and proliferation assay was performed according to the manufacturer’s instructions. Bevacizumab at 0.25, 0.5 and 0.8 mg/ml concentrations reduced RPE cell proliferation rate compared to control but anti-CTGF alone or coincident application of both bevacizumab/anti-CTGF did not motivate any significant changes in treated cultures. Each column shows comparison of specified treated culture with control culture (% of control) and each bar represents the mean ± standard deviation (SD) of at least three independent experiments performed in triplicate. *p<0.05.